Thank you for Subscribing to Apac CIO Outlook Weekly Brief
Sciformix: Leading the Pack with Trusted Services Built on Science to the Pharma & Life Science Industry
In today’s global economy, traditional business models are being pushed to the breaking point and the challenges are significant. Life Science organizations are facing a myriad of pressures from shareholders, stakeholders, regulatory authorities, patients, and the healthcare industry at large as they aim to deliver high-quality medical products around the world. Many organizations turn to outsourcing vendors to help them overcome these obstacles, but their needs have evolved this last decade as they seek a higher level of expertise in both scientific and technology prowess than what traditional Business Process Organizations (BPOs) or Contract Research Organizations (CROs) are able to offer. Sciformix Corporation is filling the gaps left by these providers and providing a higher level of engagement, quality, and value due to its thought leadership, deep domain knowledge, and technology innovation. The company differentiates itself as a Scientific & Technology Process Outsourcing (SPO) company that offers integrated process and technology services to meet the diverse needs of its clients. Its areas of specialization include Safety & Risk Management, Clinical Development, Regulatory Affairs, Real World Evidence & Market Access, and Technology Services. “We have built a wide breadth of services for life sciences businesses and with diverse scientific and technology capabilities to deliver flexible business models that are designed to meet our clients’ business needs,” says Fran Bates, Vice President, Technology Services at Sciformix Corporation.
Sciformix offers end-to-end integrated services spanning the complete spectrum of the product lifecycle
According to Fran, amongst the critical challenges organizations face is the lack of IT expertise required to efficiently access scientific and medical knowledge across all aspects of the product lifecycle. “Organizations typically prioritize, and therefore staff, drug discovery efforts over building end-to-end scientific and technological processes required for product success,” he adds. Sciformix’s capabilities help address this crital industry bottleneck. The company supports its clients by helping them build “Pharmacovigilance IT” architecture, deploy signal detection applications, and create enterprise portals for safety reporting and analytics. Alongside employing these solutions, clients are able to adhere to and effectively maintain regulatory compliance and technology validation requirements. By facilitating continuous improvement across the entire drug development lifecycle, Sciformix helps organizations to innovate, simplify, and constantly revamp their operations.
One of Sciformix’s clients, a global pharmaceutical company that offers prescription drugs and is actively engaged in R&D, had been struggling to deal with its multiple subsidiaries, each having safety data in disparate systems. Consequently, it was difficult for the organization to access the data, make informed decisions, and manage reporting to regulatory authorities. The company needed to centralize and streamline its safety data. Given this scenario, Sciformix employed its Sciformix Accelerator Methodology to ensure that every aspect of the project was planned and executed timely and efficiently. By implementing this flexible and state-of-art IT QMS and virtualization methodology, Sciformix was able to deliver a validated Sciformix Cloud safety database solution in less than 38 days.
“Innovation is a core value at Sciformix,” stresses Fran. Moreover, the zeal of innovating enables Sciformix to recognize and exploit opportunities for technological transformations that facilitate their abilities to implement extraordinary practices. Fuelled by an unrivaled commitment to quality, Sciformix aims to continue providing its clients outstanding services and solutions, and being agile, flexible, and scalable while expanding its global footprint via organic and inorganic avenues.